




Searching News Database: Janssen-Cilag
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
HSMN NewsFeed - 15 Oct 2007
Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
HSMN NewsFeed - 17 Jul 2007
Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole
Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole
HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
HSMN NewsFeed - 10 Aug 2006
Dacogen(TM) (Decitabine) for Injection Receives U.S. Orphan Drug Designation for Patients with AML
Dacogen(TM) (Decitabine) for Injection Receives U.S. Orphan Drug Designation for Patients with AML
HSMN NewsFeed - 1 Aug 2006
Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML
Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML
HSMN NewsFeed - 12 Jun 2006
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
HSMN NewsFeed - 23 May 2006
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
HSMN NewsFeed - 5 May 2006
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
HSMN NewsFeed - 13 Apr 2006
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
HSMN NewsFeed - 17 Feb 2006
Alkermes Announces Submission of Complete Response to FDA for VIVITROL(TM) New Drug Application
Alkermes Announces Submission of Complete Response to FDA for VIVITROL(TM) New Drug Application
HSMN NewsFeed - 30 Jan 2006
European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
Additional items found! 50

Members Archive contains
50 additional stories matching:
Janssen-Cilag
(Password required)
Janssen-Cilag
(Password required)